Giulia Milano, Stefano Forestieri, Micol Tedeschi, Amelia Licari, Valeria Brazzelli, Gian Luigi Marseglia
{"title":"小儿特应性皮炎的生物疗法--综述。","authors":"Giulia Milano, Stefano Forestieri, Micol Tedeschi, Amelia Licari, Valeria Brazzelli, Gian Luigi Marseglia","doi":"10.2174/1573396320666230912103136","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis (AD) is the most frequent chronic-recurrent inflammatory skin disease in the pediatric age. It has a complex and multifactorial pathogenesis: the two key actors are impaired skin barrier function and immune system dysregulation, which represent the main targets of AD therapy. Monoclonal antibodies have revolutionized the management of moderate-to-severe AD, by selective inhibition of key cytokines in the pathogenetic process. For this reason, there is great interest in exploring AD pathogenetic mechanisms to develop new therapeutic strategies. This review aims to summarize the most recent scientific evidence on available and future biological therapies for the treatment of pediatric AD, emphasizing the molecular mechanisms underlying their action.</p>","PeriodicalId":11175,"journal":{"name":"Current Pediatric Reviews","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biological Therapies for Pediatric Atopic Dermatitis - A Review.\",\"authors\":\"Giulia Milano, Stefano Forestieri, Micol Tedeschi, Amelia Licari, Valeria Brazzelli, Gian Luigi Marseglia\",\"doi\":\"10.2174/1573396320666230912103136\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Atopic dermatitis (AD) is the most frequent chronic-recurrent inflammatory skin disease in the pediatric age. It has a complex and multifactorial pathogenesis: the two key actors are impaired skin barrier function and immune system dysregulation, which represent the main targets of AD therapy. Monoclonal antibodies have revolutionized the management of moderate-to-severe AD, by selective inhibition of key cytokines in the pathogenetic process. For this reason, there is great interest in exploring AD pathogenetic mechanisms to develop new therapeutic strategies. This review aims to summarize the most recent scientific evidence on available and future biological therapies for the treatment of pediatric AD, emphasizing the molecular mechanisms underlying their action.</p>\",\"PeriodicalId\":11175,\"journal\":{\"name\":\"Current Pediatric Reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Pediatric Reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1573396320666230912103136\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pediatric Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573396320666230912103136","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PEDIATRICS","Score":null,"Total":0}
引用次数: 0
摘要
特应性皮炎(AD)是儿科最常见的慢性复发性炎症性皮肤病。特应性皮炎的发病机制复杂且多因素:两个关键因素是皮肤屏障功能受损和免疫系统失调,它们是特应性皮炎治疗的主要目标。单克隆抗体通过选择性抑制致病过程中的关键细胞因子,彻底改变了中重度 AD 的治疗方法。因此,人们对探索AD的发病机制以开发新的治疗策略产生了浓厚的兴趣。本综述旨在总结治疗儿科AD的现有和未来生物疗法的最新科学证据,强调其作用的分子机制。
Biological Therapies for Pediatric Atopic Dermatitis - A Review.
Atopic dermatitis (AD) is the most frequent chronic-recurrent inflammatory skin disease in the pediatric age. It has a complex and multifactorial pathogenesis: the two key actors are impaired skin barrier function and immune system dysregulation, which represent the main targets of AD therapy. Monoclonal antibodies have revolutionized the management of moderate-to-severe AD, by selective inhibition of key cytokines in the pathogenetic process. For this reason, there is great interest in exploring AD pathogenetic mechanisms to develop new therapeutic strategies. This review aims to summarize the most recent scientific evidence on available and future biological therapies for the treatment of pediatric AD, emphasizing the molecular mechanisms underlying their action.
期刊介绍:
Current Pediatric Reviews publishes frontier reviews on all the latest advances in pediatric medicine. The journal’s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians in pediatric medicine.